Convection-enhanced delivery: From mechanisms to clinical drug delivery for diseases of the central nervous system

Ryuta Saito, Teiji Tominaga

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)


The evolution of cancer chemotherapy has been a major advance in medical science in the late 20th century. However, patients with malignant gliomas have not benefitted much. The blood-brain barrier (BBB), which always hinders the entry of therapeutic agents into the central nervous system (CNS), may at least partly be responsible. Convection-enhanced delivery (CED), a method for distributing large and small molecular weight compounds bypassing the BBB, enables robust distribution of the infused molecules at the site of infusion. CED is promising as an effective treatment not only for malignant gliomas but also for multiple CNS disorders because this method can effectively distribute multiple molecules that are potentially effective against different diseases. Although the method is quite simple, several problems require solution in developing novel CED-based strategies, including what, where, when, and how to infuse. This review discusses basic considerations when developing CED-based strategies for CNS diseases, focusing mainly on brain tumors.

Original languageEnglish
Pages (from-to)531-538
Number of pages8
JournalNeurologia medico-chirurgica
Issue number8
Publication statusPublished - 2012


  • Blood-brain barrier
  • Brain tumor
  • Central nervous system
  • Convection-enhanced delivery
  • Drug delivery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Convection-enhanced delivery: From mechanisms to clinical drug delivery for diseases of the central nervous system'. Together they form a unique fingerprint.

Cite this